These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24441398)

  • 21. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
    Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
    Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axl inhibitors as novel cancer therapeutic agents.
    Shen Y; Chen X; He J; Liao D; Zu X
    Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells.
    Russo V; Paciocco A; Affinito A; Roscigno G; Fiore D; Palma F; Galasso M; Volinia S; Fiorelli A; Esposito CL; Nuzzo S; Inghirami G; de Franciscis V; Condorelli G
    Mol Ther Nucleic Acids; 2018 Dec; 13():334-346. PubMed ID: 30340138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 30. AXL kinase as a novel target for cancer therapy.
    Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
    Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells.
    Cho CY; Huang JS; Shiah SG; Chung SY; Lay JD; Yang YY; Lai GM; Cheng AL; Chen LT; Chuang SE
    RNA; 2016 Feb; 22(2):303-15. PubMed ID: 26667302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
    Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
    Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.
    Liu S; Li D; Guo J; Canale N; Li X; Liu R; Krasnoperov V; Gill PS; Conti PS; Shan H; Li Z
    Mol Pharm; 2014 Nov; 11(11):3974-9. PubMed ID: 24978094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
    Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
    Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.
    Jurek PM; Zabłocki K; Waśko U; Mazurek MP; Otlewski J; Jeleń F
    Int J Nanomedicine; 2017; 12():2941-2950. PubMed ID: 28442904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic aspects of the Axl/Gas6 molecular system.
    Di Stasi R; De Rosa L; D'Andrea LD
    Drug Discov Today; 2020 Dec; 25(12):2130-2148. PubMed ID: 33002607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Giving AXL the axe: targeting AXL in human malignancy.
    Gay CM; Balaji K; Byers LA
    Br J Cancer; 2017 Feb; 116(4):415-423. PubMed ID: 28072762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.